GH56 Monotherapy for Second-line Treatment of MTAP-Deleted ESCC

November 10, 2026 updated by: Suzhou Genhouse Bio Co., Ltd.

A Multicenter, Open-Label Study to Evaluate Efficacy and Safety of GH56 Monotherapy for Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma With MTAP Deficiency

This is a Phase 2/3, open-label, multicenter study to evaluate the efficacy and safety of GH56 as a single agent in participants with advanced Esophageal Squamous Cell Carcinoma(ESCC) with methylthioadenosine phosphorylase (MTAP) deficiency in the second-line or later setting. In this seamlessly designed Phase 2/3 study, a single-arm Phase 2 study will be conducted first, and after favorable efficacy data are obtained, a Phase 3 study comparing against standard chemotherapy will then be conducted.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Signed written informed consent, voluntarily participating in this study.
  2. Age ≥ 18 years, male or female.
  3. Patients with histopathologically or cytologically confirmed esophageal squamous cell carcinoma who cannot be treated surgically and have failed 1L standard of care (SoC) .
  4. MTAP deficiency is confirmed by IHC or NGS .
  5. At least one measurable lesion as per RECIST v1.1 criteria.
  6. ECOG performance status of 0 or 1.
  7. Life expectancy > 3 months.
  8. Adequate hematopoietic function, cardiac function, liver function, renal function, and coagulation function per local laboratory.
  9. Has a negative serum pregnancy test result at screening and is able to comply with contraceptive-barrier requirements.

Exclusion Criteria:

  1. Previous anti-tumor treatments did not meet the elution deadline requirements specified in the protocol; .
  2. Known or suspected that there is an allergy to GH56 active ingredients and/or GH56 capsule excipients;
  3. Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor.
  4. Tumor invasion of the central nervous system, large blood vessels, trachea, serosal cavity, and other areas may have a significant impact on the compliance, safety, and efficacy evaluation of this trial .
  5. Patients cannot take oral medication or has severe absorption disorders .
  6. Unresolved toxicity from prior anti-cancer therapy.
  7. Patients with uncontrolled clinical symptoms or disease such as other malignant tumors, cardiovascular and cerebrovascular diseases, nervous/mental diseases, respiratory diseases, digestive diseases, immune and infectious diseases.
  8. Active infection of HIV, HBV, syphilis or HCV .
  9. Conditions that the investigator considers inappropriate for participation in this clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: GH56 Capsule Group

GH56 RP2D administered to patients with MTAP-Deleted ESCC

Planned dose administered on specified days per protocol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective Response Rate (ORR)
Time Frame: Approximately 2 years

The percentage of participants having complete response (CR) or partial response (PR) assessed based on RECIST V1.1

Approximately 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression-Free Survival (PFS)
Time Frame: Approximately 2 years

Progression-Free Survival assessed by investigators based RECIST v1.1

Approximately 2 years
Overall Survival (OS)
Time Frame: Approximately 2 years

Overall Survival after first dose

Approximately 2 years
Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE)
Time Frame: Approximately 2 years

Adverse events (AEs) are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests will be recorded as TEAEs

Approximately 2 years
Pharmacokinetic characteristics of GH56
Time Frame: Approximately 2 years

Plasma Concentration of GH56

Approximately 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: bo Zheng Song, Doctorate, Zhejiang Cancer Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 31, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • GH56C204

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.